Rhythm Pharmaceuticals Q2 revenue up 67% yr/yr, net loss widens

Overview

• Rhythm Pharmaceuticals Q2 2025 product revenue rises 67% yr/yr to $48.5 mln

• However, net loss widens to $46.6 mln

• Co raised $189.2 mln in upsized public offering, strengthening financial position

Outlook

• Rhythm expects Q3 2025 regulatory submissions for setmelanotide

• Company anticipates $285 mln to $315 mln in 2025 Non-GAAP Operating Expenses

• Rhythm plans to disclose Phase 2 Prader-Willi trial results in H2 2025

• Company expects cash reserves to fund operations for at least 24 months

Result Drivers

• IMCIVREE SALES - Revenue growth driven by increased sales of IMCIVREE for Bardet-Biedl syndrome treatment

• CLINICAL TRIAL SUCCESS - Positive Phase 2 and Phase 3 trial results for bivamelagon and setmelanotide in acquired hypothalamic obesity

• EXPENSES - R&D and SG&A expenses rose sharply, affecting net income

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $103.50, about 12.8% above its August 4 closing price of $90.24

Press Release: ID:nGNX9MC9MQ